Q & A With Olympian Scott Hamilton: Turning Cancer Upside Down
September 29, 2016 – Laura Panjwani
Prostate Cancer Screening: Where Do We Stand?
September 29, 2016
Hormonal Therapy for Prostate Cancer: A Closer Look
September 29, 2016
Another Reason for Excitement About Cancer Immunotherapy
September 23, 2016 – Mike Hennessy, Sr.
Prioritizing Clinical Trials Led to New Therapies for Kidney Cancer
September 23, 2016 – Debu Tripathy, M.D.
Cystectomy to Treat Bladder Cancer: It's Complicated
September 28, 2016 – Leah K. Lawrence and CURE staff
Honing in on Bladder Cancer: Key Facts
September 28, 2016 – Arlene Weintraub and CURE staff
On the Side: An Overview of Prostate Cancer Treatment Side Effects
September 27, 2016 – Beth Fand Incollingo
From Rags to Riches: Bladder Cancer Research Rife With New Approaches
September 27, 2016 – Arlene Weintraub
Hard to Hear: Cisplatin Can Cause Hearing Loss for Men With Testicular Cancer
September 23, 2016 – Karen Bruno
A Sign of the Times: The Changing Treatment Landscape for Advanced Kidney Cancer
September 23, 2016 – Marijke Vroomen Durning, RN
Creating a Diversion: Life After Cystectomy for Bladder Cancer
September 22, 2016 – Leah K. Lawrence
Forward March: Push Continues for Immunotherapy in Prostate Cancer
September 20, 2016 – Aimee Swartz
Q & A With Olympian Scott Hamilton: Turning Cancer Upside Down
September 29, 2016 – Laura Panjwani
Prostate Cancer Screening: Where Do We Stand?
September 29, 2016
Currently Viewing
Hormonal Therapy for Prostate Cancer: A Closer Look
September 29, 2016
Prioritizing Clinical Trials Led to New Therapies for Kidney Cancer
September 23, 2016 – Debu Tripathy, M.D.
Cystectomy to Treat Bladder Cancer: It's Complicated
September 28, 2016 – Leah K. Lawrence and CURE staff
Honing in on Bladder Cancer: Key Facts
September 28, 2016 – Arlene Weintraub and CURE staff
On the Side: An Overview of Prostate Cancer Treatment Side Effects
September 27, 2016 – Beth Fand Incollingo
From Rags to Riches: Bladder Cancer Research Rife With New Approaches
September 27, 2016 – Arlene Weintraub
Hard to Hear: Cisplatin Can Cause Hearing Loss for Men With Testicular Cancer
September 23, 2016 – Karen Bruno
A Sign of the Times: The Changing Treatment Landscape for Advanced Kidney Cancer
September 23, 2016 – Marijke Vroomen Durning, RN
Creating a Diversion: Life After Cystectomy for Bladder Cancer
September 22, 2016 – Leah K. Lawrence
Forward March: Push Continues for Immunotherapy in Prostate Cancer
September 20, 2016 – Aimee Swartz

Hormonal Therapy for Prostate Cancer: A Closer Look

Not all patients with prostate cancer benefit from the same therapies. Here's a look at some of the hormone therapy options available.
PUBLISHED September 29, 2016

While hormone therapies are effective in many men who have prostate cancer, not all such patients benefit from these treatments. For some, they may not work at all. For others, they may only work for a while and then stop working. Fortunately, there are more options than ever before available to help men who have castration-resistant prostate cancer, an advanced form of prostate cancer that has gotten worse after hormone therapy or surgery: 

Zytiga (abiraterone acetate) and Xtandi (enzalutamide) share some similarities. Zytiga blocks the production of androgens, and Xtandi works a bit differently to block the androgen receptor.

Zytiga, which is given in combination with prednisone, was originally approved as a treatment for men whose prostate cancer had gotten worse after treatment with Taxotere (docetaxel) chemotherapy, but is now more often used in patients with metastatic castration-resistant prostate cancer prior to receiving chemotherapy. Similar to Zytiga’s most recent indication, Xtandi is approved to treat men with metastatic castration-resistant prostate cancer that has not been treated with chemotherapy but has spread or recurred after hormone therapy or surgery. 

Experimental agents include apalutamide, a drug similar to enzalutamide but with less central nervous system penetration, which could potentially result in reduced levels of fatigue and risk of seizures, and ODM-201, meant for patients who do not have metastatic disease. 

Be the first to discuss this article on CURE's forum. >>
Talk about this article with other patients, caregivers, and advocates in the Prostate Cancer CURE discussion group.

Related Articles

1
×

Sign In

Not a member? Sign up now!
×

Sign Up

Are you a member? Please Log In